{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:09:41Z","timestamp":1790172581957,"version":"4.1.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA232491"],"award-info":[{"award-number":["U01CA232491"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA138313"],"award-info":[{"award-number":["P30 CA138313"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2210981"],"award-info":[{"award-number":["W81XWH2210981"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Leukemia stem cells (LSCs) are a small yet powerful subset of leukemic cells that possess the ability to self-renew and have a long-term tumorigenic capacity, playing a crucial role in both leukemia development and therapy resistance. These LSCs are influenced by external and internal factors within the bone marrow niche. By delving into the intricate interplay between LSCs and their immune environment, we can pave the way for innovative immunotherapies that target both the malignant stem cells and the suppressive immune microenvironment, addressing both the \u201cseed\u201d and the \u201csoil\u201d simultaneously. Through the analysis of public datasets and patient samples, we show that elevated IL1RL1 expression correlates with poor prognosis and therapy resistance in acute myeloid leukemia (AML). At the core of this process, stem cell leukemogenesis initiation and maintenance signals are driven by a stress-induced IL-33\/IL1RL1 autocrine loop. This LSC-induced IL-33\/IL1RL1 signaling fosters an immune regulatory microenvironment. Therefore, IL1RL1 emerges as a promising therapeutic target, with IL1RL1-specific T cell-engaging bispecific antibodies holding great potential as cutting-edge immunotherapeutics for AML.<\/jats:p>","DOI":"10.1038\/s41467-025-61567-7","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T09:03:09Z","timestamp":1752483789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33\/IL1RL1 pathway"],"prefix":"10.1038","volume":"16","author":[{"given":"Denggang","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9600-326X","authenticated-orcid":false,"given":"Alan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maegan L.","family":"Capitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Wrangle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua R.","family":"Faust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anilkumar","family":"Gopalakrishnapillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5770-7187","authenticated-orcid":false,"given":"Santhosh Kumar","family":"Pasupuleti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2206-5720","authenticated-orcid":false,"given":"Baskar","family":"Ramdas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-1700","authenticated-orcid":false,"given":"Reuben","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4162-3004","authenticated-orcid":false,"given":"Sonali P.","family":"Barwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6323-5171","authenticated-orcid":false,"given":"Nai-Kong V.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5571-2775","authenticated-orcid":false,"given":"Sophie","family":"Paczesny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"61567_CR1","doi-asserted-by":"publisher","first-page":"djx030","DOI":"10.1093\/jnci\/djx030","volume":"109","author":"A Jemal","year":"2017","unstructured":"Jemal, A. et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J. Natl. Cancer Inst. 109, djx030 (2017).","journal-title":"J. Natl. Cancer Inst."},{"key":"61567_CR2","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","volume":"26","author":"A Burd","year":"2020","unstructured":"Burd, A. et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat. Med. 26, 1852\u20131858 (2020).","journal-title":"Nat. Med."},{"key":"61567_CR3","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","volume":"39","author":"C Garlanda","year":"2013","unstructured":"Garlanda, C., Dinarello, C. A. & Mantovani, A. The interleukin-1 family: back to the future. Immunity 39, 1003\u20131018 (2013).","journal-title":"Immunity"},{"key":"61567_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3389\/fimmu.2017.00475","volume":"8","author":"B Griesenauer","year":"2017","unstructured":"Griesenauer, B. & Paczesny, S. The ST2\/IL-33 Axis in immune cells during inflammatory diseases. Front. Immunol. 8, 475 (2017).","journal-title":"Front. Immunol."},{"key":"61567_CR5","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1158\/0008-5472.CAN-13-2797","volume":"74","author":"A Levescot","year":"2014","unstructured":"Levescot, A. et al. BCR-ABL-induced deregulation of the IL-33\/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients. Cancer Res. 74, 2669\u20132676 (2014).","journal-title":"Cancer Res."},{"key":"61567_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41388-022-02575-5","volume":"42","author":"JW Kwon","year":"2023","unstructured":"Kwon, J. W. et al. A synergistic partnership between IL-33\/ST2 and Wnt pathway through Bcl-xL drives gastric cancer stemness and metastasis. Oncogene 42, 501\u2013515 (2023).","journal-title":"Oncogene"},{"key":"61567_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-38408-3","volume":"9","author":"Y Wang","year":"2019","unstructured":"Wang, Y., Richter, L., Becker, M., Amador, C. & Hyde, R. K. IL1RL1 is dynamically expressed on Cbfb-MYH11(+) leukemia stem cells and promotes cell survival. Sci. Rep. 9, 1729 (2019).","journal-title":"Sci. Rep."},{"key":"61567_CR8","doi-asserted-by":"publisher","first-page":"e136073","DOI":"10.1172\/jci.insight.136073","volume":"5","author":"K Van der Jeught","year":"2020","unstructured":"Van der Jeught, K. et al. ST2 as checkpoint target for colorectal cancer immunotherapy. JCI Insight 5, e136073 (2020).","journal-title":"JCI Insight"},{"key":"61567_CR9","doi-asserted-by":"publisher","first-page":"e1062966","DOI":"10.1080\/2162402X.2015.1062966","volume":"5","author":"KD Mertz","year":"2016","unstructured":"Mertz, K. D. et al. The IL-33\/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. Oncoimmunology 5, e1062966 (2016).","journal-title":"Oncoimmunology"},{"key":"61567_CR10","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1172\/JCI77347","volume":"125","author":"LF Mager","year":"2015","unstructured":"Mager, L. F. et al. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. J. Clin. Investig. 125, 2579\u20132591 (2015).","journal-title":"J. Clin. Investig."},{"key":"61567_CR11","doi-asserted-by":"publisher","first-page":"eaay1813","DOI":"10.1126\/science.aay1813","volume":"369","author":"S Taniguchi","year":"2020","unstructured":"Taniguchi, S. et al. Tumor-initiating cells establish an IL-33-TGF-beta niche signaling loop to promote cancer progression. Science 369, eaay1813 (2020).","journal-title":"Science"},{"key":"61567_CR12","doi-asserted-by":"publisher","first-page":"102435","DOI":"10.1016\/j.bcmd.2020.102435","volume":"84","author":"ML Capitano","year":"2020","unstructured":"Capitano, M. L. et al. The IL-33 Receptor\/ST2 acts as a positive regulator of functional mouse bone marrow hematopoietic stem and progenitor cells. Blood Cells Mol. Dis. 84, 102435 (2020).","journal-title":"Blood Cells Mol. Dis."},{"key":"61567_CR13","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.bbmt.2019.05.030","volume":"25","author":"C Alt","year":"2019","unstructured":"Alt, C. et al. Long-acting IL-33 mobilizes high-quality hematopoietic stem and progenitor cells more efficiently than granulocyte colony-stimulating factor or AMD3100. Biol. Blood Marrow Transpl. 25, 1475\u20131485 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"61567_CR14","doi-asserted-by":"publisher","first-page":"963689723117737","DOI":"10.1177\/09636897231177377","volume":"32","author":"R Guan","year":"2023","unstructured":"Guan, R. et al. Interleukin-33 potentiates TGF-beta signaling to regulate intestinal stem cell regeneration after radiation injury. Cell Transpl. 32, 9636897231177377 (2023).","journal-title":"Cell Transpl."},{"key":"61567_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13287-019-1221-1","volume":"10","author":"P Huang","year":"2019","unstructured":"Huang, P. et al. Interleukin-33 regulates hematopoietic stem cell regeneration after radiation injury. Stem Cell Res. Ther. 10, 123 (2019).","journal-title":"Stem Cell Res. Ther."},{"key":"61567_CR16","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen, P. et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell 176, 1265\u20131281 e1224 (2019).","journal-title":"Cell"},{"key":"61567_CR17","doi-asserted-by":"publisher","first-page":"308ra160","DOI":"10.1126\/scitranslmed.aab0166","volume":"7","author":"J Zhang","year":"2015","unstructured":"Zhang, J. et al. ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Sci. Transl. Med. 7, 308ra160 (2015).","journal-title":"Sci. Transl. Med."},{"key":"61567_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33244-6","volume":"13","author":"BJ Huang","year":"2022","unstructured":"Huang, B. J. et al. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. Nat. Commun. 13, 5487 (2022).","journal-title":"Nat. Commun."},{"key":"61567_CR19","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3324\/haematol.2017.178442","volume":"103","author":"T Herold","year":"2018","unstructured":"Herold, T. et al. A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia. Haematologica 103, 456\u2013465 (2018).","journal-title":"Haematologica"},{"key":"61567_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/gcc.20500","volume":"47","author":"DL Stirewalt","year":"2008","unstructured":"Stirewalt, D. L. et al. Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer 47, 8\u201320 (2008).","journal-title":"Genes Chromosomes Cancer"},{"key":"61567_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3324\/haematol.13299","volume":"94","author":"RG Verhaak","year":"2009","unstructured":"Verhaak, R. G. et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 94, 131\u2013134 (2009).","journal-title":"Haematologica"},{"key":"61567_CR22","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1200\/JCO.2009.23.4732","volume":"28","author":"T Haferlach","year":"2010","unstructured":"Haferlach, T. et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J. Clin. Oncol. 28, 2529\u20132537 (2010).","journal-title":"J. Clin. Oncol."},{"key":"61567_CR23","doi-asserted-by":"publisher","first-page":"eadd7705","DOI":"10.1126\/scisignal.add7705","volume":"16","author":"P Naef","year":"2023","unstructured":"Naef, P. et al. IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways. Sci. Signal. 16, eadd7705 (2023).","journal-title":"Sci. Signal."},{"key":"61567_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).","journal-title":"Genome Biol."},{"key":"61567_CR25","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng, S. W. et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540, 433\u2013437 (2016).","journal-title":"Nature"},{"key":"61567_CR26","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1073\/pnas.0900089106","volume":"106","author":"R Majeti","year":"2009","unstructured":"Majeti, R. et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc. Natl. Acad. Sci. USA 106, 3396\u20133401 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"61567_CR27","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1182\/blood-2013-02-485771","volume":"123","author":"N Rapin","year":"2014","unstructured":"Rapin, N. et al. Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. Blood 123, 894\u2013904 (2014).","journal-title":"Blood"},{"key":"61567_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-3-6","volume":"3","author":"A Andersson","year":"2010","unstructured":"Andersson, A., Eden, P., Olofsson, T. & Fioretos, T. Gene expression signatures in childhood acute leukemias are largely unique and distinct from those of normal tissues and other malignancies. BMC Med. Genom. 3, 6 (2010).","journal-title":"BMC Med. Genom."},{"key":"61567_CR29","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.cell.2011.01.004","volume":"144","author":"N Novershtern","year":"2011","unstructured":"Novershtern, N. et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 144, 296\u2013309 (2011).","journal-title":"Cell"},{"key":"61567_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45691-4","volume":"15","author":"SG Kellaway","year":"2024","unstructured":"Kellaway, S. G. et al. Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth. Nat. Commun. 15, 1359 (2024).","journal-title":"Nat. Commun."},{"key":"61567_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45737-7","volume":"15","author":"W Jin","year":"2024","unstructured":"Jin, W. et al. Cellular hierarchy insights reveal leukemic stem-like cells and early death risk in acute promyelocytic leukemia. Nat. Commun. 15, 1423 (2024).","journal-title":"Nat. Commun."},{"key":"61567_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ccell.2016.05.011","volume":"30","author":"V Stavropoulou","year":"2016","unstructured":"Stavropoulou, V. et al. MLL-AF9 expression in hematopoietic stem cells drives a highly invasive AML expressing EMT-related genes linked to poor outcome. Cancer Cell 30, 43\u201358 (2016).","journal-title":"Cancer Cell"},{"key":"61567_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13542-2","volume":"10","author":"S Chen","year":"2019","unstructured":"Chen, S. et al. Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway. Nat. Commun. 10, 5649 (2019).","journal-title":"Nat. Commun."},{"key":"61567_CR34","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1172\/JCI84565","volume":"126","author":"J Ghosh","year":"2016","unstructured":"Ghosh, J. et al. S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance. J. Clin. Invest 126, 2621\u20132625 (2016).","journal-title":"J. Clin. Invest"},{"key":"61567_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.stem.2018.10.016","volume":"24","author":"SM Park","year":"2019","unstructured":"Park, S. M. et al. IKZF2 drives leukemia stem cell self-renewal and inhibits myeloid differentiation. Cell Stem Cell 24, 153\u2013165 e157 (2019).","journal-title":"Cell Stem Cell"},{"key":"61567_CR36","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1038\/onc.2016.488","volume":"36","author":"KHM Prange","year":"2017","unstructured":"Prange, K. H. M. et al. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia. Oncogene 36, 3346\u20133356 (2017).","journal-title":"Oncogene"},{"key":"61567_CR37","doi-asserted-by":"publisher","first-page":"11994","DOI":"10.1073\/pnas.1310656110","volume":"110","author":"H Huang","year":"2013","unstructured":"Huang, H. et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc. Natl. Acad. Sci. USA 110, 11994\u201311999 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"61567_CR38","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1182\/blood-2006-04-016030","volume":"108","author":"M Murakami","year":"2006","unstructured":"Murakami, M. et al. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes\/macrophages. Blood 108, 1849\u20131856 (2006).","journal-title":"Blood"},{"key":"61567_CR39","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.stem.2014.06.018","volume":"15","author":"GA Challen","year":"2014","unstructured":"Challen, G. A. et al. Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells. Cell Stem Cell 15, 350\u2013364 (2014).","journal-title":"Cell Stem Cell"},{"key":"61567_CR40","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1111\/cas.14033","volume":"110","author":"Y Chu","year":"2019","unstructured":"Chu, Y. et al. Six1 regulates leukemia stem cell maintenance in acute myeloid leukemia. Cancer Sci. 110, 2200\u20132210 (2019).","journal-title":"Cancer Sci."},{"key":"61567_CR41","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.3324\/haematol.2020.254987","volume":"106","author":"B De Boer","year":"2021","unstructured":"De Boer, B. et al. The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis. Haematologica 106, 3067\u20133078 (2021).","journal-title":"Haematologica"},{"key":"61567_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.exphem.2021.01.003","volume":"95","author":"NF Russkamp","year":"2021","unstructured":"Russkamp, N. F., Myburgh, R., Kiefer, J. D., Neri, D. & Manz, M. G. Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells. Exp. Hematol. 95, 31\u201345 (2021).","journal-title":"Exp. Hematol."},{"key":"61567_CR43","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.exphem.2016.04.012","volume":"44","author":"U Testa","year":"2016","unstructured":"Testa, U., Labbaye, C., Castelli, G. & Pelosi, E. Oxidative stress and hypoxia in normal and leukemic stem cells. Exp. Hematol. 44, 540\u2013560 (2016).","journal-title":"Exp. Hematol."},{"key":"61567_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nature07618","volume":"457","author":"A Viale","year":"2009","unstructured":"Viale, A. et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 457, 51\u201356 (2009).","journal-title":"Nature"},{"key":"61567_CR45","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/eji.201242863","volume":"43","author":"CS Hardman","year":"2013","unstructured":"Hardman, C. S., Panova, V. & McKenzie, A. N. IL-33 citrine reporter mice reveal the temporal and spatial expression of IL-33 during allergic lung inflammation. Eur. J. Immunol. 43, 488\u2013498 (2013).","journal-title":"Eur. J. Immunol."},{"key":"61567_CR46","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1182\/blood-2011-05-356238","volume":"118","author":"HE Kohrt","year":"2011","unstructured":"Kohrt, H. E. et al. Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation. Blood 118, 5319\u20135329 (2011).","journal-title":"Blood"},{"key":"61567_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02384-y","volume":"18","author":"B Zhou","year":"2020","unstructured":"Zhou, B. et al. WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target. J. Transl. Med. 18, 254 (2020).","journal-title":"J. Transl. Med."},{"key":"61567_CR48","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1089\/hyb.2010.0100","volume":"30","author":"N Fursov","year":"2011","unstructured":"Fursov, N. et al. Generation and characterization of rat anti-mouse ST2L monoclonal antibodies. Hybridoma 30, 153\u2013162 (2011).","journal-title":"Hybridoma"},{"key":"61567_CR49","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1158\/2326-6066.CIR-14-0230-T","volume":"3","author":"H Xu","year":"2015","unstructured":"Xu, H. et al. Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody. Cancer Immunol. Res. 3, 266\u2013277 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"61567_CR50","doi-asserted-by":"publisher","first-page":"eaax1315","DOI":"10.1126\/scitranslmed.aax1315","volume":"12","author":"BH Santich","year":"2020","unstructured":"Santich, B. H. et al. Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies. Sci. Transl. Med. 12, eaax1315 (2020).","journal-title":"Sci. Transl. Med."},{"key":"61567_CR51","doi-asserted-by":"publisher","first-page":"e002222","DOI":"10.1136\/jitc-2020-002222","volume":"9","author":"JA Park","year":"2021","unstructured":"Park, J. A., Santich, B. H., Xu, H., Lum, L. G. & Cheung, N. V. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release. J. Immunother. Cancer 9, e002222 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"61567_CR52","doi-asserted-by":"publisher","first-page":"e1320625","DOI":"10.1080\/2162402X.2017.1320625","volume":"6","author":"SS Hoseini","year":"2017","unstructured":"Hoseini, S. S., Dobrenkov, K., Pankov, D., Xu, X. L. & Cheung, N. K. Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2. Oncoimmunology 6, e1320625 (2017).","journal-title":"Oncoimmunology"},{"key":"61567_CR53","doi-asserted-by":"publisher","first-page":"6664","DOI":"10.4049\/jimmunol.181.9.6664","volume":"181","author":"L Baudino","year":"2008","unstructured":"Baudino, L. et al. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J. Immunol. 181, 6664\u20136669 (2008).","journal-title":"J. Immunol."},{"key":"61567_CR54","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1158\/2326-6066.CIR-19-0121","volume":"7","author":"L Wang","year":"2019","unstructured":"Wang, L., Hoseini, S. S., Xu, H., Ponomarev, V. & Cheung, N. K. Silencing Fc domains in T cell-engaging bispecific antibodies improves T-cell trafficking and antitumor potency. Cancer Immunol. Res. 7, 2013\u20132024 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"61567_CR55","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.molimm.2016.05.019","volume":"75","author":"N Fursov","year":"2016","unstructured":"Fursov, N. et al. Monoclonal antibodies targeting ST2L Domain 1 or Domain 3 differentially modulate IL-33-induced cytokine release by human mast cell and basophilic cell lines. Mol. Immunol. 75, 178\u2013187 (2016).","journal-title":"Mol. Immunol."},{"key":"61567_CR56","doi-asserted-by":"publisher","first-page":"eabd1524","DOI":"10.1126\/scitranslmed.abd1524","volume":"13","author":"B Belmontes","year":"2021","unstructured":"Belmontes, B. et al. Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors. Sci. Transl. Med. 13, eabd1524 (2021).","journal-title":"Sci. Transl. Med."},{"key":"61567_CR57","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","volume":"19","author":"JM Wrangle","year":"2018","unstructured":"Wrangle, J. M. et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 19, 694\u2013704 (2018).","journal-title":"Lancet Oncol."},{"key":"61567_CR58","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1158\/2159-8290.CD-16-0008","volume":"6","author":"SE Meyer","year":"2016","unstructured":"Meyer, S. E. et al. DNMT3A haploinsufficiency transforms FLT3ITD myeloproliferative disease into a rapid, spontaneous, and fully penetrant acute myeloid leukemia. Cancer Discov. 6, 501\u2013515 (2016).","journal-title":"Cancer Discov."},{"key":"61567_CR59","doi-asserted-by":"publisher","first-page":"eaay4799","DOI":"10.1126\/scitranslmed.aay4799","volume":"12","author":"D Adom","year":"2020","unstructured":"Adom, D. et al. ICOSL(+) plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS\/CD28 antagonist. Sci. Transl. Med. 12, eaay4799 (2020).","journal-title":"Sci. Transl. Med."},{"key":"61567_CR60","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fonc.2016.00162","volume":"6","author":"A Gopalakrishnapillai","year":"2016","unstructured":"Gopalakrishnapillai, A. et al. Generation of pediatric leukemia xenograft models in NSG-B2m mice: comparison with NOD\/SCID mice. Front. Oncol. 6, 162 (2016).","journal-title":"Front. Oncol."},{"key":"61567_CR61","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1365-2249.2009.03933.x","volume":"157","author":"MA King","year":"2009","unstructured":"King, M. A. et al. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin. Exp. Immunol. 157, 104\u2013118 (2009).","journal-title":"Clin. Exp. Immunol."},{"key":"61567_CR62","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/0300985820970144","volume":"58","author":"LJ Janke","year":"2021","unstructured":"Janke, L. J. et al. Development of mast cell and eosinophil hyperplasia and HLH\/MAS-Like disease in NSG-SGM3 mice receiving human CD34+ hematopoietic stem cells or patient-derived leukemia xenografts. Vet. Pathol. 58, 181\u2013204 (2021).","journal-title":"Vet. Pathol."},{"key":"61567_CR63","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1089\/scd.2015.0289","volume":"25","author":"AM Coughlan","year":"2016","unstructured":"Coughlan, A. M. et al. Myeloid engraftment in humanized mice: impact of granulocyte-colony stimulating factor treatment and transgenic mouse strain. Stem Cells Dev. 25, 530\u2013541 (2016).","journal-title":"Stem Cells Dev."},{"key":"61567_CR64","doi-asserted-by":"publisher","first-page":"1893500","DOI":"10.1080\/2162402X.2021.1893500","volume":"10","author":"H Xu","year":"2021","unstructured":"Xu, H., Buhtoiarov, I. N., Guo, H. & Cheung, N. V. A novel multimeric IL15\/IL15Ralpha-Fc complex to enhance cancer immunotherapy. Oncoimmunology 10, 1893500 (2021).","journal-title":"Oncoimmunology"},{"key":"61567_CR65","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"61567_CR66","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1093\/jnci\/djab131","volume":"113","author":"F Islami","year":"2021","unstructured":"Islami, F. et al. Annual Report to the Nation on the status of cancer, part 1: national cancer statistics. J. Natl. Cancer Inst. 113, 1648\u20131669 (2021).","journal-title":"J. Natl. Cancer Inst."},{"key":"61567_CR67","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/ni1080","volume":"5","author":"KJ Hope","year":"2004","unstructured":"Hope, K. J., Jin, L. & Dick, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 5, 738\u2013743 (2004).","journal-title":"Nat. Immunol."},{"key":"61567_CR68","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","volume":"20","author":"D Vetrie","year":"2020","unstructured":"Vetrie, D., Helgason, G. V. & Copland, M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat. Rev. Cancer 20, 158\u2013173 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"61567_CR69","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","volume":"18","author":"A Carey","year":"2017","unstructured":"Carey, A. et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 18, 3204\u20133218 (2017).","journal-title":"Cell Rep."},{"key":"61567_CR70","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1111\/bjh.16873","volume":"190","author":"JW Day","year":"2020","unstructured":"Day, J. W., Fox, T. A., Halsey, R., Carpenter, B. & Kottaridis, P. D. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement. Br. J. Haematol. 190, e80\u2013e83 (2020).","journal-title":"Br. J. Haematol."},{"key":"61567_CR71","doi-asserted-by":"publisher","first-page":"1000996","DOI":"10.3389\/fimmu.2022.1000996","volume":"13","author":"M Luciano","year":"2022","unstructured":"Luciano, M., Krenn, P. W. & Horejs-Hoeck, J. The cytokine network in acute myeloid leukemia. Front. Immunol. 13, 1000996 (2022).","journal-title":"Front. Immunol."},{"key":"61567_CR72","doi-asserted-by":"publisher","first-page":"298ra119","DOI":"10.1126\/scitranslmed.aab1740","volume":"7","author":"C Riether","year":"2015","unstructured":"Riether, C. et al. Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. Sci. Transl. Med. 7, 298ra119 (2015).","journal-title":"Sci. Transl. Med."},{"key":"61567_CR73","doi-asserted-by":"publisher","first-page":"jem.20190787","DOI":"10.1084\/jem.20190787","volume":"217","author":"YA Kang","year":"2020","unstructured":"Kang, Y. A., Pietras, E. M. & Passegue, E. Deregulated Notch and Wnt signaling activates early-stage myeloid regeneration pathways in leukemia. J. Exp. Med. 217, jem.20190787 (2020).","journal-title":"J. Exp. Med."},{"key":"61567_CR74","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nature01593","volume":"423","author":"T Reya","year":"2003","unstructured":"Reya, T. et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423, 409\u2013414 (2003).","journal-title":"Nature"},{"key":"61567_CR75","first-page":"13","volume":"1","author":"H Zhang","year":"2014","unstructured":"Zhang, H., Fang, H. & Wang, K. Reactive oxygen species in eradicating acute myeloid leukemic stem cells. Stem Cell Investig. 1, 13 (2014).","journal-title":"Stem Cell Investig."},{"key":"61567_CR76","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nature13577","volume":"513","author":"C Schiering","year":"2014","unstructured":"Schiering, C. et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513, 564\u2013568 (2014).","journal-title":"Nature"},{"key":"61567_CR77","doi-asserted-by":"publisher","first-page":"e1063772","DOI":"10.1080\/2162402X.2015.1063772","volume":"5","author":"P Xiao","year":"2016","unstructured":"Xiao, P. et al. Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells. Oncoimmunology 5, e1063772 (2016).","journal-title":"Oncoimmunology"},{"key":"61567_CR78","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","volume":"123","author":"S Gill","year":"2014","unstructured":"Gill, S. et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 123, 2343\u20132354 (2014).","journal-title":"Blood"},{"key":"61567_CR79","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nm1483","volume":"12","author":"L Jin","year":"2006","unstructured":"Jin, L., Hope, K. J., Zhai, Q., Smadja-Joffe, F. & Dick, J. E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12, 1167\u20131174 (2006).","journal-title":"Nat. Med."},{"key":"61567_CR80","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti, R. et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286\u2013299 (2009).","journal-title":"Cell"},{"key":"61567_CR81","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood.2020008221","volume":"138","author":"T Sauer","year":"2021","unstructured":"Sauer, T. et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood 138, 318\u2013330 (2021).","journal-title":"Blood"},{"key":"61567_CR82","doi-asserted-by":"publisher","first-page":"11008","DOI":"10.1073\/pnas.0704271104","volume":"104","author":"N Hosen","year":"2007","unstructured":"Hosen, N. et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc. Natl. Acad. Sci. USA 104, 11008\u201311013 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"61567_CR83","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","volume":"110","author":"A van Rhenen","year":"2007","unstructured":"van Rhenen, A. et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 110, 2659\u20132666 (2007).","journal-title":"Blood"},{"key":"61567_CR84","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1182\/bloodadvances.2021004424","volume":"5","author":"AJ Kaeding","year":"2021","unstructured":"Kaeding, A. J. et al. Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia. Blood Adv. 5, 2350\u20132361 (2021).","journal-title":"Blood Adv."},{"key":"61567_CR85","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1182\/blood-2016-10-696039","volume":"129","author":"DA Pollyea","year":"2017","unstructured":"Pollyea, D. A. & Jordan, C. T. Therapeutic targeting of acute myeloid leukemia stem cells. Blood 129, 1627\u20131635 (2017).","journal-title":"Blood"},{"key":"61567_CR86","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1073\/pnas.1820388116","volume":"116","author":"M Onda","year":"2019","unstructured":"Onda, M., Kobayashi, K. & Pastan, I. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity. Proc. Natl. Acad. Sci. USA 116, 4575\u20134582 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"61567_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22885-8","volume":"12","author":"Z Amoozgar","year":"2021","unstructured":"Amoozgar, Z. et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat. Commun. 12, 2582 (2021).","journal-title":"Nat. Commun."},{"key":"61567_CR88","doi-asserted-by":"publisher","first-page":"e2200757119","DOI":"10.1073\/pnas.2200757119","volume":"119","author":"AE Wight","year":"2022","unstructured":"Wight, A. E. et al. Antibody-mediated blockade of the IL23 receptor destabilizes intratumoral regulatory T cells and enhances immunotherapy. Proc. Natl. Acad. Sci. USA 119, e2200757119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"61567_CR89","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/ni.3799","volume":"18","author":"M Delacher","year":"2017","unstructured":"Delacher, M. et al. Genome-wide DNA-methylation landscape defines specialization of regulatory T cells in tissues. Nat. Immunol. 18, 1160\u20131172 (2017).","journal-title":"Nat. Immunol."},{"key":"61567_CR90","doi-asserted-by":"publisher","first-page":"e99208","DOI":"10.1172\/jci.insight.99208","volume":"3","author":"AM Ramadan","year":"2018","unstructured":"Ramadan, A. M. et al. From proteomics to discovery of first-in-class ST2 inhibitors active in vivo. JCI Insight 3, e99208 (2018).","journal-title":"JCI Insight"},{"key":"61567_CR91","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1084\/jem.191.6.1069","volume":"191","author":"MJ Townsend","year":"2000","unstructured":"Townsend, M. J., Fallon, P. G., Matthews, D. J., Jolin, H. E. & McKenzie, A. N. T1\/ST2-deficient mice demonstrate the importance of T1\/ST2 in developing primary T helper cell type 2 responses. J. Exp. Med. 191, 1069\u20131076 (2000).","journal-title":"J. Exp. Med."},{"key":"61567_CR92","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","volume":"10","author":"AJ Yousuf","year":"2022","unstructured":"Yousuf, A. J. et al. Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respir. Med. 10, 469\u2013477 (2022).","journal-title":"Lancet Respir. Med."},{"key":"61567_CR93","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","volume":"148","author":"SG Kelsen","year":"2021","unstructured":"Kelsen, S. G. et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial. J. Allergy Clin. Immunol. 148, 790\u2013798 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"61567_CR94","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2411680","volume":"392","author":"S Gupta","year":"2024","unstructured":"Gupta, S. et al. Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children. N. Engl. J. Med. 392, 875\u2013891 (2024).","journal-title":"N. Engl. J. Med."},{"key":"61567_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06746-y","volume":"15","author":"YE Yang","year":"2024","unstructured":"Yang, Y. E. et al. IL-33\/NF-kappaB\/ST2L\/Rab37 positive-feedback loop promotes M2 macrophage to limit chemotherapeutic efficacy in lung cancer. Cell Death Dis. 15, 356 (2024).","journal-title":"Cell Death Dis."},{"key":"61567_CR96","doi-asserted-by":"publisher","first-page":"5468","DOI":"10.1172\/JCI130520","volume":"129","author":"R Pandey","year":"2019","unstructured":"Pandey, R. et al. SHP2 inhibition reduces leukemogenesis in models of combined genetic and epigenetic mutations. J. Clin. Invest 129, 5468\u20135473 (2019).","journal-title":"J. Clin. Invest"},{"key":"61567_CR97","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882\u2013883 (2012).","journal-title":"Bioinformatics"},{"key":"61567_CR98","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccr.2006.08.020","volume":"10","author":"TC Somervaille","year":"2006","unstructured":"Somervaille, T. C. & Cleary, M. L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10, 257\u2013268 (2006).","journal-title":"Cancer Cell"},{"key":"61567_CR99","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nm0896-876","volume":"2","author":"H Hanenberg","year":"1996","unstructured":"Hanenberg, H. et al. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat. Med. 2, 876\u2013882 (1996).","journal-title":"Nat. Med."},{"key":"61567_CR100","doi-asserted-by":"publisher","first-page":"634847","DOI":"10.3389\/fimmu.2021.634847","volume":"12","author":"J Chen","year":"2021","unstructured":"Chen, J. et al. Increased dysfunctional and plastic regulatory T cells in idiopathic orbital inflammation. Front. Immunol. 12, 634847 (2021).","journal-title":"Front. Immunol."},{"key":"61567_CR101","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1084\/jem.20170041","volume":"214","author":"A Ramadan","year":"2017","unstructured":"Ramadan, A. et al. Specifically differentiated T cell subset promotes tumor immunity over fatal immunity. J. Exp. Med. 214, 3577\u20133596 (2017).","journal-title":"J. Exp. Med."},{"key":"61567_CR102","doi-asserted-by":"publisher","first-page":"e1168557","DOI":"10.1080\/2162402X.2016.1168557","volume":"5","author":"M Cheng","year":"2016","unstructured":"Cheng, M. et al. Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors. Oncoimmunology 5, e1168557 (2016).","journal-title":"Oncoimmunology"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61567-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61567-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61567-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T05:39:57Z","timestamp":1757223597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61567-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["61567"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-61567-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"28 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.-K.V.C. reports receiving commercial research grants from Y-mabs Therapeutics and Abpro-Labs Inc.; holding ownership interest\/equity in Y-Mabs Therapeutics Inc., holding ownership interest\/equity in Abpro-Labs, and owning stock options in Eureka Therapeutics. N.-K.V.C. is the inventor and owner of issued patents licensed by Memorial Sloan Kettering Cancer Center (MSKCC) to Ymabs Therapeutics, Biotec Pharmacon, and Abpro-labs. Both MSKCC and N.-K.V.C. have financial interest in Y-mabs. N.-K.V.C. is an advisory board member for Abpro-Labs and Eureka Therapeutics. Otherwise, the authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6369"}}